http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2021158841-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_6dd31aa32e5e59ae066132ae32bc85ad |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-16734 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-137 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-20 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-135 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-138 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-137 |
| filingDate | 2021-02-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_26678a3e19ca482f494a9faae581fdfd |
| publicationDate | 2021-08-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | WO-2021158841-A1 |
| titleOfInvention | Treatment and dosing regimen for s1p receptor modulator |
| abstract | The present invention relates to a dosage regimen of an S1P receptor modulator or agonist in the course of the treatment of patients suffering from an inflammatory or autoimmune disease or disorder, for example multiple sclerosis (MS). By administering a S1P receptor modulator or agonist, such as Fingolimod, according to the dosage regimen, it is possible to treat the patient efficiently while controlling, reducing, or eliminating possible adverse events, e.g. infection, recurrence of infection, or reactivation of latent infection, which may be associated with administration of such a compound. |
| priorityDate | 2020-02-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 135.